Dr. David Bristol will present his new online course, “Adaptive/Group
Sequential Designs for Clinical Trials” at statistics.com, Jan. 27 – Feb. 24.
The “pipeline problem” – a slowdown in innovative medical therapies
reaching patients – is now a major concern of pharmaceutical firms,
regulatory authorities, CRO’s, and related organizations. Clinical trial
designs with greater flexibility (without sacrificing statistical validity)
are a key element in addressing this crisis.
This course will introduce interim monitoring and adaptive methods for the
design, monitoring and analysis of clinical trials. Participants will
become acquainted with statistically sound principles that incorporate
interim looks at the data, possible early stopping, and interim
re-estimation of power and required sample size. It covers group sequential
designs and adaptive methods of sample size re-estimation. After taking
this course, participants will be able to assess when and whether these
methods might be appropriate for use in their own clinical trials.
Dr. Bristol is a leading expert in the design and implementation of
clinical trials. As Director of Biostatistics for Purdue Pharma and of
Biometrics (Cardiovascular) for Pfizer, he has coordinated statistical
activities, including clinical trials, for the development programs for a
number of drugs. He has also worked with Sanofi and Schering Plough.
Participants will interact with Dr. Bristol via a private discussion board;
the course will require about 10 hours per week and there are no set hours
when you must be online.
Registration and details at
http://www.statistics.com/content/courses/adaptive/index.html
Peter Bruce
|